Drug Trial Radar · NCT06353997
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 5, 2024
Primary completion
Jun 2027
Study completion Jun 2029
Sponsor
- Lead sponsor
- Providence Health & ServicesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Inhibrx Biosciences, Inc
- First posted
- Apr 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
Conditions
- Triple Negative Breast Cancer
Interventions
PembrolizumabDrug
Drug will be delivered per standard-of-care as established by trial Keynote-522.
INBRX-106Drug
INBRX-106 is a hexavalent, recombinant humanized IgG1, OX40 agonist antibody that targets the human OX40 receptor (TNFRSF4, UniProtKB: P43489). INBRX-106 is based on a sdAb platform and, in detail, 3 identical humanized camelid heavy chain-only antibody binding domains (VHHs) targeting OX40 are joined end-to-end and with an Fc based on human IgG1 to create a molecule that homo-dimerizes into an antibody targeting a total of 6 OX40 receptors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Volumetric ResponseTime frame: At the end of Cycle 2 (each cycle is 21 days)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Ellison Institute of Technology (EITM)
Los Angeles, California · Recruiting
Providence Portland Cancer Institute - Franz Clinic
Portland, Oregon · Recruiting
Providence St. Vincent Medical Center
Portland, Oregon · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.